PDGFRB and breast carcinoma: For example, increased expression of PDGFRβ has been associated with enhanced cell migration and invasion in breast cancer [31]; BreastMark identifies PDGFRβ as a marker of poor prognosis and this RTK has been shown to be inhibited by imatinib in phase I clinical trials [48].